Navigation Links
Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences

Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences -- CARMIEL, Israel, Oct. 25 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Trade Show News Click to view news release full screen  

Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences


CARMIEL, Israel, Oct. 25 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE: PLX), announced today that Dr. David Aviezer, the Company's President and Chief Executive Officer, will present at the Oppenheimer 21st Annual Healthcare Conference in New York and the World Orphan Drug Congress 2010 in Geneva. The conference schedule is as follows:Oppenheimer 21st Annual Healthcare ConferenceCorporate Presentation, November 2 at 12:00 PM ETWaldorf Astoria Hotel, New York, NYA webcast of this presentation will be available at on the event calendar pageWorld Orphan Drug Congress 2010Presentation, November 30 at 9:10 AM CESTCrown Plaza Hotel, Geneva, SwitzerlandAbout ProtalixProtalix is a biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins expressed through its proprietary plant cell based expression system.  Protalix's ProCellEx™ presents a proprietary method for the expression of recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins in an environment free of mammalian components and viruses.  Protalix is also advancing additional recombinant biopharmaceutical drug development programs.  Taliglucerase alfa is an enzyme replacement therapy in development under a Special Protocol Assessment with the FDA for Gaucher disease. The Company's new drug application (NDA) for taliglucerase alfa has been accepted by the U.S. Food and Drug Administration (FDA) and granted a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.

Investor Contact: Marcy NanusThe Trout Group, LLCTelephone: 646-378-2927Email:

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs
2. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
3. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
4. Talecris Biotherapeutics Receives FDA Approval for Gamunex®-C
5. Talecris Biotherapeutics to Report Third Quarter 2010 Financial Results
6. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
7. Garnet BioTherapeutics Announces First Patient Treated in Trial of New Therapy for Improvement in Scar Appearance
8. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
9. Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing
10. Oxygen Biotherapeutics, Inc. Expands Board of Directors
11. Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland
Post Your Comments:
(Date:11/25/2015)... 25, 2015  The American Academy of Pediatrics ... and the March of Dimes cheered today,s signature ... Infants Act of 2015 (S.799), which takes ... born exposed to drugs, such as opioids, and ... all three organizations have worked together leading advocacy ...
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
(Date:11/25/2015)... TEL AVIV, Israel , November 25, 2015 /PRNewswire/ ... Ltd. (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical ... the simultaneous treatment of various clinical conditions, today announced ... of 3,158,900 American Depository Shares ( ADSs ), each ... to purchase up to 3,158,900 ADSs. The ADSs and ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... 29, 2015 , ... Effective immediately, every single IguanaMed scrub style will be ... Target is offering a “Buy One Scrub Set, Get the 2nd Scrub Set 50% ... IguanaMed at a discounted price. , IguanaMed’s mission is to outfit every ...
(Date:11/28/2015)... ... November 28, 2015 , ... Safe storage for contraceptive devices may not ... from Lakewood, New Jersey and the other from Bradley Beach, New Jersey, there is ... the expense of having to replace NuvaRings more often than necessary. As such, it ...
(Date:11/28/2015)... CA (PRWEB) , ... November 28, 2015 , ... Pixel ... fully customizable media panels to choose from, the possibilities are endless. Users have full ... more. With the ProPanel: Pulse masking effects, users are sure to get heads to ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... study carried out by the University of Toronto and the University of British Columbia ... of hospitalizations for head injuries. The article explains that part of the reason for ...
(Date:11/27/2015)... ... ... A team of Swiss doctors has released a report on mesothelioma relapse ... the findings on the website. Click here to read the details now. ... who were treated with chemotherapy followed by EPP surgery. Among the 106 patients who ...
Breaking Medicine News(10 mins):